neostigmine has been researched along with Acute Confusional Senile Dementia in 12 studies
Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.
neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with Alzheimer's disease participated in a trial of two sessions in which they received physostigmine and neostigmine in a double-blind crossover design." | 2.66 | Cortisol responses to cholinergic drugs in Alzheimer's disease. ( Ashford, W; Colliver, J; Giacobini, E; Kumar, V; Murphy, J; Sherman, KA; Smith, RC, 1988) |
| "In 2-month-old mice, no β-amyloid plaques deposition, but the presence of soluble oligomers, were found in CA1 area but not in dentate gyrus (DG)." | 1.42 | Region- and age-dependent reductions of hippocampal long-term potentiation and NMDA to AMPA ratio in a genetic model of Alzheimer's disease. ( Borsello, T; Calabresi, P; Costa, C; de Iure, A; Di Filippo, M; Ghiglieri, V; Sclip, A; Tantucci, M; Tozzi, A, 2015) |
| "Irinotecan (CPT-11) is an anticancer drug that occasionally produces acute cholinergic side effects." | 1.30 | The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11). ( Dodds, HM; Rivory, LP, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Khan, I | 1 |
| Ibrar, A | 1 |
| Zaib, S | 1 |
| Ahmad, S | 1 |
| Furtmann, N | 2 |
| Hameed, S | 1 |
| Simpson, J | 1 |
| Bajorath, J | 3 |
| Iqbal, J | 3 |
| Hameed, A | 2 |
| Zehra, ST | 2 |
| Shah, SJ | 1 |
| Khan, KM | 2 |
| Alharthy, RD | 1 |
| Tahir, MN | 1 |
| Abbas, S | 1 |
| Nisa, RU | 1 |
| Mahmood, T | 1 |
| Ayub, K | 1 |
| Al-Rashida, M | 1 |
| Xu, M | 1 |
| Peng, Y | 1 |
| Zhu, L | 1 |
| Wang, S | 1 |
| Ji, J | 1 |
| Rakesh, KP | 1 |
| Blaikie, L | 1 |
| Kay, G | 1 |
| Kong Thoo Lin, P | 1 |
| Sato, T | 1 |
| Nakatsuka, H | 1 |
| Tozzi, A | 1 |
| Sclip, A | 1 |
| Tantucci, M | 1 |
| de Iure, A | 1 |
| Ghiglieri, V | 1 |
| Costa, C | 1 |
| Di Filippo, M | 1 |
| Borsello, T | 1 |
| Calabresi, P | 1 |
| Prohovnik, I | 1 |
| Arnold, SE | 1 |
| Smith, G | 1 |
| Lucas, LR | 1 |
| Dodds, HM | 1 |
| Rivory, LP | 1 |
| Kaur, J | 1 |
| Zhang, MQ | 1 |
| Umegaki, H | 1 |
| Tamaya, N | 1 |
| Shinkai, T | 1 |
| Iguchi, A | 1 |
| Kumar, V | 1 |
| Smith, RC | 1 |
| Sherman, KA | 1 |
| Ashford, W | 1 |
| Murphy, J | 1 |
| Giacobini, E | 1 |
| Colliver, J | 1 |
2 reviews available for neostigmine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Triazole derivatives as inhibitors of Alzheimer's disease: Current developments and structure-activity relationships.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Resp | 2019 |
Molecular modelling and QSAR of reversible acetylcholines-terase inhibitors.
Topics: Alkaloids; Alzheimer Disease; Cholinesterase Inhibitors; Crystallography, X-Ray; Donepezil; Drug Des | 2000 |
1 trial available for neostigmine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Cortisol responses to cholinergic drugs in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterases; Clinical Trials as Topic; Cognition; Do | 1988 |
9 other studies available for neostigmine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Active compounds from a diverse library of triazolothiadiazole and triazolothiadiazine scaffolds: synthesis, crystal structure determination, cytotoxicity, cholinesterase inhibitory activity, and binding mode analysis.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cell Line, Tumor; Chloroceb | 2014 |
Syntheses, cholinesterases inhibition, and molecular docking studies of pyrido[2,3-b]pyrazine derivatives.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Drug Desi | 2015 |
One-pot synthesis of tetrazole-1,2,5,6-tetrahydronicotinonitriles and cholinesterase inhibition: Probing the plausible reaction mechanism via computational studies.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinergic Agents; Cholinesterase I | 2016 |
Synthesis and in vitro evaluation of vanillin derivatives as multi-target therapeutics for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Antioxidants; Benzaldehydes; Biphenyl Compounds; Butyrylcho | 2020 |
[Anticholinesterases; peripheral and central effects].
Topics: Alzheimer Disease; Brain; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Neostigmine; Neuromu | 2013 |
Region- and age-dependent reductions of hippocampal long-term potentiation and NMDA to AMPA ratio in a genetic model of Alzheimer's disease.
Topics: Aging; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Amyloid beta-Pro | 2015 |
Physostigmine reversal of scopolamine-induced hypofrontality.
Topics: Acetylcholine; Adult; Alzheimer Disease; Amnesia; Blood-Brain Barrier; Cerebrovascular Circulation; | 1997 |
The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11).
Topics: Acetylcholinesterase; Acylation; Alzheimer Disease; Binding, Competitive; Butyrylcholinesterase; Cam | 1999 |
The metabolism of plasma glucose and catecholamines in Alzheimer's disease.
Topics: Acetylcholine; Aged; Aged, 80 and over; Aging; Alzheimer Disease; Animals; Blood Glucose; Catecholam | 2000 |